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Are carer attitudes toward medications related to self-reported medication
adherence amongst people with mental illness?
Abstract
Medication nonadherence among consumers with psychiatric disorders can significantly affect the health
and wellbeing of the consumer and their family. Previous research has suggested that carers have an
impact on consumer attitudes toward medication and adherence. Yet, how carer attitudes toward
medication may be related to consumer attitudes and adherence has received little investigation. This
exploratory study aimed to investigate the relationships between carer and consumer attitudes toward
medication and consumer adherence behaviour. A cross-sectional survey assessing consumer and carer
attitudes toward medication and consumer adherence was conducted amongst 42 consumer-carer
dyads. Correlation analyses showed a positive association between consumer and carer attitudes toward
medication and between consumer and carer attitudes with adherence. There was a general indication
that the greater the difference between consumer and carer attitudes, the lower the level of adherence.
Regression analyses revealed that while neither consumer nor carer attitudes were significant predictors
of adherence, carer attitudes appeared to have a stronger role in adherence than consumer attitudes.
These preliminary results highlight the importance of carer attitudes in relation to patient perceptions and
behaviours toward medication, and thus the potential benefits of addressing both consumer and carer
attitudes in any intervention for improving adherence.
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1. Introduction
Pharmacotherapy is generally recognised as an important component in the
treatment and management of schizophrenia, bipolar, and depression (Barnes and British
Assoc, 2011; Cleare et al., 2015; Goodwin et al., 2016). Yet, nonadherence to medication
has been reported as greater than 50% amongst mental health consumers for these
disorders (Castle et al., 2012; Ibrahim et al., 2015; Levin et al., 2016; Shafrin et al.,
2016). Non-adherence has been defined as clinically significant deviation from the
dosage prescribed and exists on a continuum from completely adherent, through levels of
partial adherence, to not taking medication at all (Aslani and du Pasquier, 2002).
Complete or even partial nonadherence may significantly affect the health and wellbeing
of the consumer and their family and has considerable financial implications for the
health system (Ascher-Svanum et al., 2006; Gilmer et al., 2004; Hudson et al., 2004;
Lacro et al., 2002). Non-adherence in schizophrenia often results in illness exacerbation,
relapse, and increased re-hospitalisation (Coombs et al., 2003; Day et al., 2005; Dolder et
al., 2003; Kikkert et al., 2008; Lacro et al., 2002; Marland and Cash, 2001; Rettenbacher
et al., 2004).
A number of factors have been identified as contributing to medication
nonadherence such as psychopathology, cognitive impairment, insight, number and
severity of side effects, complexity of dosing pattern, clinician skill, and social support
(Fleishchacker et al., 2003). This paper focuses on how consumer and carer attitudes
impact adherence.
Previous research has established the importance of subjective attitudes and
beliefs of consumers towards their illness and medication in promoting medication
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adherence. Consumers who hold negative beliefs and attitudes towards medication, are
less likely to engage in adherence behaviour, while consumers with positive beliefs tend
to have higher medication adherence (Lacro et al., 2002; Loffler et al., 2003;
Rettenbacher et al., 2004). Rettenbacher et al (2004) found a positive correlation
between medication adherence and the consumer’s subjective belief as to whether they
felt the drug had a positive effect on their illness. It was also found that adherent
consumers more often reported the positive effect of medication on their illness and
indicated this to be a reason for taking medication in comparison to nonadherent
consumers. Similarly, a study among psychiatric consumers in Norway reported that
nonadherent consumers felt medication to be less necessary and were more concerned
about it than adherent consumers (Jonsdottir et al., 2009).
Less research has examined how the attitudes of individuals such as family
members who care for the consumer may shape consumer adherence. Consumer
subjective attitudes and beliefs towards medication are developed within an environment
in which a consumer is likely to draw on multiple sources of information (Byrne et al.,
2008). These sources of information include those significant people around them. In a
study of 122 consumers with bipolar disorder more positive medication attitudes were
predicted by higher levels of social support and stronger beliefs that their health is
influenced by important people in their social environment (Chang et al., 2015).It has
been suggested that negative attitudes towards treatment in patients’ social environments
can have adverse effects on adherence and that it is important to reinforce positive
attitudes toward treatment for both patients and relatives (Fleischhacker et al., 2003).
Other research has shown an association between carer and consumer attitudes about
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their illness or treatment and found that carer attitudes can impact consumer outcomes. A
Latin American study of consumers with schizophrenia and their carers investigated the
association between causal belief of schizophrenia with attitudes toward medicine and
symptoms (Caqueo-Urizar et al., 2015). Consumer and carer causal beliefs shared small
to moderate correlations (e.g., biological causal belief r=.45). Stronger consumer and
carer “magical-religious causal belief” were significantly associated with more negative
attitudes toward medicine (r=-0.18 and r=-0.13 respectively). Carers having stronger
beliefs in magical-religious causes of mental illness were associated with greater
symptom severity in their family member (r=0.22, Caquero-Urizar et al., 2015). A
systematic review of medication adherence among Asian Americans with mental illness
found that the most successful interventions used psychoeducation that included both
consumers and carers, and improved knowledge and attitudes among consumers and
family caregivers coincided with clinical improvement (Fancher et al., 2014).
Overall, research has demonstrated the potential impact carers have on consumer
attitudes toward medication and the potential effects of consumer and carer beliefs on
adherence outcomes. It is important to note that previous research has tended to cast
carers and family members in an assisting or supervisory role, but did not consistently
and clearly address the attitudinal nature by which this social support might influence
consumer adherence behaviour. Moreover, it is not clear from previous research whether
it is important that consumer and carer attitudes coincide for optimal adherence or
whether discrepancies between attitudes are inconsequential. The current cross-sectional
study is exploratory in nature and aims to investigate the relationships between carer and
consumer attitudes toward medication and consumer adherence behaviour. Although
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predominantly exploratory, given findings from prior research it was expected that
consumer and carer attitudes towards medication and medication adherence would be
positively correlated. The study aimed to explore whether consumer and carer attitudes or
the discrepancy between these attitudes predicted self-reported medication adherence.
2. Methods
2.1 Procedure
Eligible consumers were individuals over the age of 18 with a serious mental
illness requiring psychotropic medications and eligible carers were individuals over the
age of 18 involved in the support of these consumers.
All procedures were reviewed and approved by the relevant Human Research
Ethics Committee (HE09/104). The sample was recruited with the support of the carer
organisation Association of Relatives and Friends of the Mentally Ill (ARAFMI) in New
South Wales (NSW), Australia. Two recruitment pathways were used. Firstly, a
researcher attended carer support meetings run by ARAFMI NSW branches at Central
Coast, Illawarra and Ryde and invited carers to participate. Secondly, staff at ARAFMI
offered participation when carers rang the state head office to make an enquiry. If the
carer provided informed consent, they were mailed or emailed a questionnaire pack with
coordination of the carer organisation. The pack contained separate information sheets for
consumers and carers, separate consumer and carer questionnaires, and reply paid
envelopes. All questionnaires were matched with a code to maintain anonymity and
returned directly to the researchers via the reply paid envelopes. This was an
opportunistic convenience sample and given that staff at the ARAFMI services provided
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information to potential participants we were unable to accurately determine the response
rate.

2.2 Measures
2.2.1 Medication adherence
The Brief Adherence Rating Scale (BARS; Byerly et al., 2008) consists of four
items assessing different aspects of adherence:
1. number of prescribed doses per day;
2. how often a dose has been missed over the past month, rated from 1 (less than 7) to
4 (more than 20);
3. how often a consumer took less than prescribed dose over the past month, rated
from 1 (76-100% of the time) to 4 (0-25% of the time); and
4. overall proportion (0-100%) of doses taken over the past month.
The last item serves as the final adherence determination (Byerly et al., 2008). In a
study with 61 consumers living with schizophrenia, the BARS showed excellent internal
consistency (α=0.92) and good validity, sensitivity (73%), and specificity (71%; Byerly
et al., 2008).
The Kemp Clinician Rated Compliance Scale (CRCS; Kemp et al., 1996) comprises
a single item rating scale in which respondents rate their level of compliance with
medication on a seven-point Likert-type scale. The scale points are: 1 (complete refusal),
2 (partial refusal), 3 (reluctant acceptance), 4 (occasional reluctance), 5 (passive
acceptance), 6 (moderate participation), and 7 (active participation). The CRCS has
been found to be a valid clinician-rated measure in medication adherence studies among
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people with schizophrenia (Kemp et al., 1996; Tsang et al., 2009), and clinician and
consumer rated CRCS have shown a medium correlation in a sample of people with
schizophrenia (r=0.50; Friemann and Wciorka, 2013).The CRCS has shown a small
correlation (r=0.25; Kikkert et al., 2008) with the self-reported Medication Adherence
Questionnaire (Morisky et al., 1986).

2.2.2 Attitudes towards medication
The Drug Attitude Inventory – 10 (DAI-10; Hogan and Awad, 1992) measures
satisfaction with medication and understanding of treatment effects. It consists of 10
items that require either an agree/correct (scored 1) or disagree/incorrect (scored -1)
response. The final score ranges from -10 to 10, with the higher the positive or lower the
negative score reflecting extent of positivity or negativity towards medications. Internal
consistency using Cronbach’s alpha in the current study was 0.72 for consumers and 0.78
for carers.
The Beliefs About Medication Questionnaire (BMQ; Horne et al., 1999) – general
beliefs subscale contains 8 items that assesses perceptions of the perceived potential for
harm and overuse of medication. Items are rated using a 5-point Likert-type scale ranging
from 1 (strongly agree) to 5 (strongly disagree). Higher scores represent more negative
beliefs. The subscale has demonstrated acceptable internal consistency (>0.69) and
validity among people with mental health disorders (Horne et al., 1999; Jonsdottir et al.,
2009). Cronbach’s alpha in the current study was 0.88 for consumers and 0.85 for carers.

2.3 Analyses
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Normality plots and statistical tests of normality were inspected. Results showed
that the CRCS, BARS and DAI scores did not meet normality assumptions. Therefore we
applied the nonparametric tests of Spearman’s correlations and bootstrapping for t-tests
and regression analyses (5,000 samples).
For all analyses we were interested in examining both consumer and carer
reported adherence. This enabled judgments to be made about how results might be
impacted by different respondent groups. Also, a composite adherence measure was
calculated using standardized scores on the CRCS and BARS4 (overall proportion of
doses taken in prior month). The purpose was to maximize use of the adherence data and
improve reliability from using single item scores only. The composite scores showed
acceptable internal consistency for carers (α=0.76) and marginally acceptable internal
consistency for consumers (α=0.66).
Spearman’s correlations were used to test the associations between consumer and
carer attitudes and adherence. Paired t-tests with bootstrapping were also used to detect
any differences between carer and consumer scores on attitudinal and adherence
measures. Attitude discrepancy was tested by calculating difference scores between
consumer and carer attitude measures (BMQ and DAI). These difference scores were
then correlated with consumer and carer rated adherence.
Finally, the prediction of adherence was tested using regression analysis with
bootstrapping. Separate multiple regressions with bootstrapping on the consumer and
carer adherence composite scores were performed. In order to determine the variables to
include in a regression analysis, correlations and t-tests were conducted between carer
and consumer composite adherences scores with demographic and clinical characteristics
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and both consumer and carer attitude measures. Given that use of difference scores as
predictors in multiple regression usually leads to loss of model fit (Edwards, 2001), when
a difference score and an individual score from which it was calculated (e.g. BMQ
difference score and consumer BMQ score) both correlated significantly with the
composite adherence score, we selected the individual scores for the regression.

3. Results
3.1 Sample characteristics
The sample consisted of 42 carers and 42 of their family members with a mental
illness who were receiving treatment (consumers). The mean age of carers was 54.61
(SD=13.48, range=19-78) and the majority of carers were female (64%). Consumers
(N=42) were equally distributed in gender and had a mean age of 41.21 (SD=14.63,
range=18-67). Australia was the most frequently reported place of birth for participants
with 79% of carers and 95% of consumers reported to be born in Australia. As shown in
Table 1, the most frequent mental health diagnosis reported was
schizophrenia/schizoaffective (43%), followed by bipolar (26%) and depression (17%).
Carers were mostly parents (48%) and the most frequently reported period of care was
over 10 years (57%).

[INSERT Table 1]

3.2 Descriptives
Frequency analysis of the CRCS adherence scale for consumers revealed that
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50% reported active participation, while 29% reported moderate participation. This is
consistent with mean consumer BARS4 scores of 91.98% (SD=19.05) adherence to
taking the recommended dosage in the past month. For carers, half (50%) reported that
consumers had active participation, 19% moderate participation, and 14% passive
acceptance. This is also largely consistent with mean carer BARS4 scores of 92.26%
(SD=19.07).

3.3 Relationships between consumers and carers medication attitudes and
adherence measures
Consumer and carer reported adherence were strongly related for both the CRCS
(r=0.67, p<0.01) and BARS4 (r=0.61, p<0.01) scores. Similarly, there was a strong
positive correlation between carer and consumer scores on both the DAI-10 (r=0.72,
p<0.01) and BMQ (r=0.66, p<0.01). Table 2 shows the results of paired t-tests with
bootstrapping (5,000 samples) between consumer and carer adherence and attitude
measures. The results indicated no significant differences between consumer and carer
reported adherence on the CRCS or BARS4 (p<0.05) or attitudes on the DAI-10 and
BMQ (p<0.05).

[INSERT Table 2]

3.4 Correlations between consumer and carer attitudes and consumer adherence
Overall, there was a positive association between consumer and carer attitudes
and adherence measures, such that the more positive the attitudes, the greater the
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adherence (see Table 3). This pattern of relationships between attitude measures and
adherence generally remains when comparing consumers and carers separately. Of note,
specific attitudes seemed to relate more consistently with adherence than general attitudes
(BMQ); carer general attitudes did not share a significant relationship with any adherence
outcome. Also, the number of days in which less than the prescribed dose was taken
(BARS3) was related to consumer attitudes only.

[INSERT Table 3]

3.5 Correlations between discrepancy in consumer and carer attitudes with
consumer adherence
Discrepancies in attitudes towards medication were correlated with both
consumer and carer ratings of adherence (Table 3). The difference in specific attitudes
(DAI-10 diff) was more consistently related to adherence than the difference in general
attitudes (BMQ diff), which was related to carer reported CRCS ratings only. The greater
the difference between consumer and carer specific attitudes, the lower the level of
adherence.

3.6 Consumer and carer attitudes predicting adherence
Separate multiple regression analyses with bootstrapping (5,000 samples) were
performed on consumer and carer composite adherence scores. Predictors entered for
consumer reported adherence were consumer and carer DAI-10 scores. Predictors entered
for carer reported adherence were consumer and carer DAI-10 scores and consumer
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BMQ score. Correlations and t-tests showed that demographic and clinical characteristics
were unrelated to the composite adherence scores (all p>0.05).
Table 4 provides a summary of the regression results. For consumers, the model
accounted for a significant 42% of the variance in consumer reported adherence
F3,41=14.28, p<0.01. There were no significant unique predictors, although carer DAI-10
approached significance (β=0.62, p=0.06). For carers, the model accounted for a
significant 43% of the variance in carer reported adherence F3,41=9.56, p<0.01).
Likewise, no predictors reached significance, although carer DAI-10 approached
significance (β=0.60, p=0.06).

[INSERT Table 4]

4. Discussion
As expected, consumer and carer adherence and attitudes towards medication were
positively related. The magnitude of the correlation suggests shared attitudes toward
medication. This research does not allow us to determine the extent or direction of
influence between consumer and carer but the association of attitudes could be a result of
a mutual influence process. It is common for carers to simultaneously hold both positive
and negative attitudes towards medication which could further influence the attitudes of a
family member with mental illness. For example, a European survey of carers of patients
with schizophrenia showed that most carers recognized the importance of medication to
help patients get better (76%) while at the same time believing it damages their general
health (67%; Svettini et al., 2015). Such concerns are legitimate given the heightened
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health risks associated with many antipsychotic medications (e.g., weight gain, new onset
diabetes). The majority agreed on the importance of family support to boost adherence
(93%), and acknowledged that treatment adherence was a burden for patients (65%), with
a notable proportion indicating that it was a daily struggle to get patients to take their
medication (38%). Although the current study provides preliminary evidence of the
relationship between carer and consumer attitudes towards medications, there is a need
for future longitudinal research in order to gain a better understanding of whether attitude
transfer between carers and consumers is a bidirectional process. Clarifying the causal
direction will help more effectively target interventions designed to improve medication
adherence.
Consumer and carer attitudes toward medication were associated with adherence,
with more positive attitudes being associated with greater adherence. Specific attitudes
(DAI-10) seemed more consistently related with adherence than general attitudes (BMQ).
This was particularly for carers where their general attitudes did not relate at all to
consumer or carer reported adherence. These initial findings suggest that, specific
attitudes regarding how medication affects the consumer personally appear more useful
in understanding adherence than more broad or general attitudes. Also, consumer reports
of taking less than the prescribed dose (BARS3) were impacted by their own attitudes
only.
Partial support was found for the discrepancy in consumer and carer attitude towards
medication correlating with adherence. In general, the findings indicated that the greater
the difference between consumer and carer attitudes, the lower the level of adherence.
The difference in DAI-10 scores was found to more consistently relate to adherence
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outcomes on the CRCS and adherence composite, while the difference in BMQ scores
related to carer reported CRCS adherence only. These results point to the importance of
including consumers and carers as collaborators in clinical decision making regarding
medication. The need to include carers in decisions about medication has been
highlighted in a qualitative study of 29 carers in Australia with most indicating that they
had been provided with little or no information about antipsychotic medication from
treatment teams (Stomski & Morrison, 2017). Most carers expressed a desire to be
involved in medication decision making but typically felt excluded from this process. The
authors concluded that “health professionals need to substantially improve the extent to
which they collaborate with carers in medication decisions” (Stomski& Morrison, 2017,
p. 7). Toward this end, it may be helpful for treating clinicians to understand and address
consumers and carers attitudes and concerns about medication given the relationship
between discrepancy in views and adherence.
The regression models found that consumer and carer attitudes accounted for a
substantial and significant amount of variance in adherence, but there were no unique
predictors, although carer specific attitudes (DAI-10) approached significance and made
a relatively strong contribution to the overall model. It is notable that carer specific
attitudes appear to have a substantial role in predicting adherence even when consumers’
specific and general attitudes are controlled. This result speaks to the importance of carer
influence in consumer medication adherence and thus the need to target both carers and
consumers with psychoeducational activities to increase adherence.
A number of limitations to this study should be mentioned. This research is specific
to an Australian sample, which impacts the generalisability of the results, while the
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relatively small sample size impacts the generalisability of the results. Given the
recruitment strategy relied on staff working within the carer support agency an accurate
response rate was not able to be determined and leaving the possibility that unknown bias
in the sample may have been introduced. In addition, because the sample was recruited
through carer support agencies there may be unknown selection effects (e.g., carers with
more knowledge of medications). It is also possible that requiring consent from both
carer and consumers may result in selection biases (e.g., more cooperative relationships).
Since this was a cross-sectional survey causal links between attitudes and medication
adherence cannot be determined. A longitudinal design in this research area would be
valuable in exploring the dynamic interplay between consumer and carer attitudes and
medication adherence. Finally, adherence was self-reported which is subject to a variety
of response biases, namely social desirability in the current study. Future research in this
area would benefit from incorporating other methodologies to determine medication
adherence for corroboration of self-report data, such as electronic monitoring systems.
Nonetheless, a strength of this study was the inclusion of multiple attitude and medication
adherence measures. In addition, the novel dyad focus on consumer and their carers
provided valuable information on the potential mutual influence processes effecting
consumer medication adherence.

4.1 Conclusions
This preliminary study suggests a strong link between consumer and carer
attitudes toward medication and a positive association between both consumer and carer
attitudes with consumer adherence. Moreover, regression analyses showed that while
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neither consumer nor carer attitudes were significant unique predictors of adherence,
carer attitudes may play as strong or stronger role in adherence than consumers’ attitudes.
In addition, there was a general indication that the greater the difference between
consumer and carer attitudes, the lower the level of adherence. These initial findings need
to be extended in larger more representative samples, but they offer tantalizing
possibilities should they be replicated in future research. Specifically, they offer
opportunities for the development of interventions that target carer and consumer
attitudes toward medication, with the potential of improving consumer medication
adherence.
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Table 1. Demographics and clinical characteristics of consumers (N=42) and carers
(N=42).
Frequency

Percent

Schizophrenia/ Schizoaffective

18

43

Bipolar

11

26

Depression

7

17

Other

6

14

Antipsychotic

29

69

Antidepressant

7

17

Not stated

4

10

Other

2

5

0-2 years

1

2

3-5 years

13

29

6-9 years

8

18

10 years and over

23

51

Mental health diagnosis

Medication type

Treatment length

22

Years as carer
0-2 years

2

5

3-5 years

8

19

6-9 years

8

19

10 years and over

24

57

Parent

20

48

Partner

15

36

Child

6

14

Friend

1

2

Carer relationship with consumer

Note. Percentages do not always add to 100 due to rounding.
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Table 2. Comparison of mean attitude and adherence scores for consumers and carers.
Consumer M(SD)

Carer M(SD)

t-value

Boot 95 CI

DAI-10

3.51 (5.08)

4.13 (4.98)

0.41

-0.71, 1.29

BMQ

2.81 (.91)

2.59 (.82)

-1.57

-0.41, 0.04

CRCS

6.02 (1.56)

5.74 (1.65)

-1.57

-0.55, 0.05

BARS4

88.84 (24.12)

91.22 (19.57)

0.23

-2.12, 2.69

Adherence

-0.02 (.89)

-0.02 (.93)

-0.58

-0.16, 0.07

composite
Note 1. DAI-10=Drug Attitude Inventory – 10; BMQ=Beliefs About Medication
Questionnaire; CRCS=Clinician Rated Compliance Scale; BARS4= Brief Adherence
Rating Scale item 4 about the proportion of doses taken.
Note 2. Boot 95 CI = bootstrap 95% confidence intervals.
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Table 3. Correlations between consumer and carer attitude and adherence measures.
Consumer

Carer
Adherence

Consumer

CRCS

DAI-10 0.28

BARS2

BARS3

BARS4

composite

Adherence
CRCS

BARS2

BARS3

BARS4

composite

-0.34*

0.31*

0.36*

0.34*

0.44**

-0.44**

0.22

0.34*

0.47**

0.42*

-0.32*

-0.14

-0.26

-0.51**

0.49**

-0.20

-0.13

-0.45**

-0.39**

0.22

0.37*

0.49**

0.62**

-0.50**

0.18

0.25

0.59**

0.20

-0.12

-0.17

-0.18

-0.25

0.30

-0.02

-0.09

-0.24

DAI-10 diff 0.45**

-0.27

0.04

0.08

0.35*

0.43*

-0.20

0.02

-0.09

0.32*

BMQ diff 0.16

-0.19

0.23

0.08

0.09

0.32*

-0.23

0.19

0.09

0.23

BMQ -0.29
Carer
DAI-10 0.46**
BMQ -0.15
Difference
scores
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* p<0.05, ** p<0.01
Note. CRCS=Clinician Rated Compliance Scale; BARS2= Brief Adherence Rating Scale item 2 about number of days did not take
medication; BARS3= Brief Adherence Rating Scale item 3 about number of days took less than prescribed number; BARS4= Brief
Adherence Rating Scale item 4 about the proportion of doses taken; DAI-10 diff=difference score between consumer and carer Drug
Attitude Inventory – 10 (DAI-10) ratings; BMQ diff= difference score between consumer and carer Beliefs About Medication
Questionnaire (BMQ) ratings.
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Table 4. Regression on consumer and carer standardized adherence scores.
Boot

% unique

b

Boot SE

95% CI

variance

Consumer DAI-10

0.01

0.03

-0.07, 0.06

0.09

Carer DAI-10

0.10

0.04

0.02, 0.19

16.24

Consumer DAI-10

-0.01

0.03

-0.09, 0.04

0.07

Consumer BMQ

-0.13

0.16

-0.45, 0.17

0.64

Carer DAI-10

0.11

0.04

0.03, 0.20

14.75

Consumer adherence
scores

Carer adherence scores

* p<0.05, ** p<0.01
Note 1. DAI-10=Drug Attitude Inventory – 10; BMQ=Beliefs About Medication
Questionnaire.
Note 2. b = unstandardised regression coefficient; Boot SE = bootstrap standard error;
Boot 95 CI = bootstrap 95% confidence intervals; % unique variance = percentage of
unique variance accounted for in the adherence score, as indicated by the squared
semipartial correlation coefficient.
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